Ryanodex — Competitive Intelligence Brief

Ryanodex (DANTROLENE) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Skeletal Muscle Relaxant. Area: Metabolic.

marketed Skeletal Muscle Relaxant Ryanodine receptor 1 Metabolic Small molecule

Target snapshot

Ryanodex (DANTROLENE) — Ph Health.

Comparator set (4 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ryanodex TARGET	DANTROLENE	Ph Health	marketed	Skeletal Muscle Relaxant	Ryanodine receptor 1	1974-01-01
Atracurium	Atracurium Besylate	Pfizer	marketed	Nondepolarizing skeletal muscle relaxant	Cholinergic receptor sites on motor end-plate	1983-01-01
Standard opioid plus methocarbamol	Standard opioid plus methocarbamol	Prisma Health-Upstate	marketed	Opioid analgesic combination with skeletal muscle relaxant	Mu-opioid receptor (opioid component); central nervous system polysynaptic pathways (methocarbamol component)
Parafon Forte	Parafon Forte	University of California, San Francisco	marketed	Centrally-acting skeletal muscle relaxant
Cyclobenzaprine with caffeine	Cyclobenzaprine with caffeine	EMS	phase 3	Skeletal muscle relaxant with CNS stimulant	Alpha-2 adrenergic receptors (cyclobenzaprine); adenosine receptors (caffeine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Skeletal Muscle Relaxant class)

1. Ph Health · 1 drug in this class